RATING

RECOMMENDATION

Strong Sell

  • ROFR Required
  • Available in Depository:

  • NSDL

  • CDSL

  • Available for Investment:

  • Primary

  • Secondary

RATING

RECOMMENDATION

Strong Sell

Business Type

Traditional Business

RATING

RECOMMENDATION

Strong Sell

Business Type

Traditional Business

If you are going to buy sell & invest in Arch Pharmalabs Unlisted Shares and need to know everything about company including net profit growth, profit & loss, peers, latest news, Arch Pharmalabs Revenue Growth, then you should always read latest research report which is already given on website.

ISIN

INE182F01017

Face Value

₹10.00

Total Share

15,19,23,076

Total Income

₹798.58 Cr

Profit After Tax

₹1,869.44 Cr

EPS

₹123.05

P/E

0.81

P/B

-2.22

Market Capitalisation

₹1,519.23 Cr

Enterprise Value

₹2,737.39 Cr

Book Value

-₹45.12

Intrinsic Value

₹185.00

Earnings Yield

123.05 %

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Delisted

Cashflow - Operations

₹278.33 Cr

Cashflow - Financing

-₹269.93 Cr

Arch Pharmalabs Growth

Compounded Sales Growth

  • 11.66%

    1 Year

  • 21.71%

    2 Year

  • 41.88%

    3 Year

Pro Only

Compounded Profit Growth

  • NA

    1 Year

  • NA

    3 Year

Pro Only

Return On Equity

  • -272.73%

    2021

  • 10.59%

    2020

  • 9.99%

    2019

Pro Only

About Arch Pharmalabs

  • Arch Pharmalabs Limited, a pharmaceutical company, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India and internationally. The company offers APIs across various therapeutic segments, such as lipid lowering agents, oncology, anti-platelet agents, anti-asthmatic, anti-retroviral, anti-anginal, calcium channel blockers, anti-hypertensive, anti-histamine, anti diabetic, anti protozoal, anti fungal, anti emetic, proton pump inhibitors, expectorant, anti depressant, decongestant, anti convulsant, psychostimulant, hypnotic, anti parkinsonian, anti gout, analgesic, and others. It also provides contract manufacturing, custom synthesis, and contract research services comprising route selection, process development, optimization, analytical development, stability studies, safety studies, scale-up to technology transfer, clinical-trial manufacturing, and commercial manufacturers
  • The company has API manufacturing facilities in Gurgaon ( Vitalife Site), Tarapur ( Oncology Site), and New Mumbai ( Dombivli Site) along with these the company also has Intermediate manufacturing facilities in Hyderabad (Merven Site & Watsol Site) and near Mumbai ( Badlapur Site & Taloja Site). Along with all this, the company has also started Contract Research and Manufacturing Services (CRAMS) to grow business vertical
  •  The company was established on 2nd April 1993 and currently has more than 590 employees.

  • Arch Pharmalabs IPO Details

Archpharma Labs had filed its draft red herring prospectus with the Securities and Exchange Board of India in 2011 to raise finance through an initial public offering (IPO). The Archpharma IPO consists of a Fresh Issue of Rs 135 crore and an Offer for Sale (OFS) of up to 6.17 million equity shares by its investor shareholders and promoter group shareholder.

Arch Pharmalabs
Fresh Issue

₹ 135.00 Cr

Arch Pharmalabs
Total IPO Size

₹ 135.00 Cr

Arch Pharmalabs
Offer for Sale No. of Shares

61,72,607 Cr

  • Arch Pharmalabs Funding

Funded By Funding Amount Date of Investment Funding Round
Mitsui & Co. Undisclosed 17 Jan 2013 Corporate
  • Arch Pharmalabs Merger & Acquisition

Acquisition

  • On November 22, 2017, Neuland Laboratories Limited (BSE:524558) acquired Arch Pharmalabs Limited's manufacturing facility in Gaddapotharam. JM Financial Asset Reconstruction Company made the purchase through the execution of a sale certificate in accordance with the provisions of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002.
  • On 17th, September 2012 Mitsui & Co, a Japanese diversified trading company, paid Rs. 372 cr. for an additional 25% stake in active pharmaceutical ingredient manufacturer Arch Pharma labs. Mitsui purchased IL&FS Trust Co, IDBI Trusteeship Services, and Rainbow Fund.
  • On 23rd, August 2007 Archpharma Labs acquired Wastol Organics in an all-cash deal for $ 300 million. 
  • Arch Pharmalabs Subsidiaries

Subsidiaries:

  • Arch Life Sciences Limited 
  • Arch Finechemicals Limited 
  • Arch Pharmalabs FZ LLC 
  • Vitalife Pharma Ltd


Associate:

  • Kobo Biotech Limited 

Arch Pharmalabs Business Model

  • Arch Pharmalabs: Arch Pharmalabs Ltd is in the business of API and Intermediates manufacturing with 8 manufacturing facilities across India. All these 8 manufacturing facilities are multipurpose with reactor capacities of around 1200 KL. The company is also in the business of  CRAMS through strategic alliances and co-marketing agreements
  • Kobo Biotech Limited: The production of Active Pharmaceutical Ingredients (API) using fermentation technology is the focus of Kobo Biotech Limited. In Solapur, Maharashtra, they have a manufacturing factory.



  • Arch Pharmalabs Revenue Segmentation

  • API/Intermediate
  • Other Sale of products
  • Other Non Operating Income
  • Interest Income on others
  • Arch Pharmalabs Product & Services

The company provides the following services :

  • API Manufacturing
  • Intermediate Manufacturing
  • Contract Services 
  • Arch Pharmalabs Assets

As of 31st March, 2021 company's fixed assets are bifurcated as follows:


Tangible Assets (in Crores)


Land Freehold199.48
Land Leasehold 42.04
Buildings184.57
Plant & Machinery 483.88
Electrical Installation10.95
Computers0.50
Furniture & Fixtures 0.47
Office Equipment 1.47
Vechiles 0.13

Intangible Assets(in Crores)


Computer Software 0.54           
Technology Transfer 1.55
Product Development Expenses0.86


  • Arch Pharmalabs Industry Overview

Industry Statistics

Introduction:

  • The pharmaceutical industry researches, develops, manufactures, and distributes pharmaceutical drugs for use as medicines to patients (or self-given), aiming to cure, immunize, or relieve their symptoms. As of FY21, generic drugs denote 75.5 % of the overall sales of the pharmaceutical sector followed by OTC medicines contributing 15.6 % and patented drugs tallying up to 8.9%. It engages in technological advancements to meet the complex healthcare demands of the population, which plays a significant role in developing vaccines and medications for the treatment of ailments, prevention, reduction of disease incidence, and enhancement of quality of life. 
  • According to Care Edge, in terms of volume and value, the Indian pharmaceutical industry (IPI) is ranked 3rd and 14th, respectively. The dominance of IPI in generic drugs, which command lower pricing and contribute to around 70% of the industry's sales, can be blamed for the lower market share in terms of value. The IPI is mainly segregated into four Formulations, API/Bulk drugs, Biosimilars, and CRAMS. 


Market:

  • According to Fitch Solutions, the pharmaceuticals market is valued at Rs. 2421.7 billion in FY21 compared to Rs. 2123.4 billion in FY20, showcasing a growth of 14% year-on-year (y-o-y). The key drivers behind the change are an increase in the market value, low cost of production, patent cliff, increase in per capita income, the transition of disease profile, an increase in the health insurance market, and abating of regulatory risks 
  • The achievement of Good Manufacturing Practice (GMP) accreditation will help the company's trade network grow and enable shipments to developed market regions. Along with this, the healthcare industry is still growing, and people are becoming more cost-conscious, leading to this exponential performance.


Key Trends:

  • The key trends in the pharmaceutical industry include Artificial intelligence, Blockchain, Patient-centric care, and Big data analytics. Big companies are using these to make the healthcare segment more advance and efficient.
  • Few negative trends in the sector are increased input cost due to the rise of import duties on Chinese products which leads to a rise in the input cost India meets its 69% demand by the imports of Chinese API/bulk drugs. This is followed by price control by government authorities to make the drug more affordable as well as relatively low Research & Development (R&D) investments because according to Care Edge the top 5 pharmaceutical companies of India only allocated 7.1% to 7.9% for their R&D CAPEX.


Major Player:

  •  Major listed players in these sectors are Sun Pharmaceutical Ltd, Cipla Ltd, Abbott India Ltd, Alkem Laboratories Ltd, and Torrent Pharmaceuticals Ltd.


Listed Peers:

  • The listed peers of Arch Pharma Labs ltd, as per its market capitalization and portfolio sizes, are Neuland Laboratories Ltd, Solara Active Pharma Sciences Ltd, and Unichem Laboratories Ltd  

Future Prospects

  • According to Fitch solutions, the Indian pharmaceutical industry is expected to reach Rs. 3830.2 billion FY25, expanding at a compound annual growth rate (CAGR) of  12.5% during the 2021-2025 period. Medicine sales would see a 10-year CAGR of 11.7% over the extended forecast period. The key drivers for the growth are the large and growing population, improved access to healthcare and the rising burden of chronic diseases. 
  • Given that India provides around 10% of global pharmaceutical production volumes and has a market share of about 2.4 percent in terms of value, the Indian pharmaceutical industry enjoys a dominant position in terms of production volumes. India's superior position is primarily due to its lower cost of production and its skilled people resources in science and technology. India has some of the lowest medicine prices in the entire globe.
  • A total of USD 240 billion worth of patented goods are anticipated to lose their patent protection during the following 5–6 years, until 2026. This offers Indian generic formulation businesses a significant potential. Due to patent expiration in the following 4-5 years, Indian pharmaceutical businesses are anticipated to receive an opportunity worth approximately USD 5–6 billion.

Government Initiatives

  • The National Regulatory Authority (NRA) of India is DSCO, which is a part of the Directorate General of Health Services under the Ministry of Health & Family Welfare of the Government of India. Its headquarters are in New Delhi, and it also has offices all over the country, including six zonal offices, four sub-zonal offices, thirteen port offices, and seven laboratories.
  • The Union Cabinet adopted plans for the pharmaceutical industry on March 21, 2020, taking into account the scenario and India's dependence on China for KSM and API. The "Promotion of Bulk Drug Parks" program will spend Rs. 3,000 cr. over the course of five years, from FY21 to FY25, to finance common infrastructure facilities in three bulk drug parks.
  • On January 3, 2021, the Indian government approved Covishield by Serum Institute of India (SII), Covaxin by AstraZeneca, and Covaxin by Bharat Biotech for restricted usage in emergency situations to support the immunization campaign in India. The government of India started a vaccination campaign on January 16, 2021, with the goal of immunizing 30 crore people by July or August of that same year.
  • The PM Ayushman Bharat Health Infrastructure Mission (PMABHIM), with a budget of Rs. 640 billion, was introduced by Prime Minister Narendra Modi in his parliamentary district of Varanasi in October 2021 to boost the nation's healthcare capacities significantly.
  • It was revealed in October 2021 that the Active Pharmaceutical Ingredient (API) sector is the focus of mergers and acquisitions because of the "Atmanirbhar" drive and increased demand for pharmaceutical raw materials made in India rather than China (M&A). The Indian API sector is appealing to investors from India and around the world because of its favorable valuations, promising future, and accredited plants.
  • Under Union budget 2020-21, allocation to the Ministry of Health and Family Welfare stands at Rs. 65,012 crores, whereas Rs. 6,429 crores have been allocated to the health insurance scheme Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (ABPMJAY).
  • 53 key KSMs, drug intermediates, and APIs have been recognized as needing domestic production through the Production Linked Incentive (PLI) Scheme, with a potential cost of Rs. 6,940 crores. The program will run from FY 2020–21 to FY 2029–30.

Arch Pharmalabs Strengths

  • Revenue from operations has increased from Rs 247.19 cr. in 2018 to Rs 798.58 cr. in 2020, showcasing a growth of 59.9% which is higher than the industry average 
  • The company has 8 manufacturing facilities that are multipurpose with reactor capacities of around 1200 KL.

Arch Pharmalabs Shortcomings

  • Company is not able to make profits from last 3 years due to high cost of materials consumed despite of increasing income of last 3 years.
  • The company's assets are decreasing over the past 3 years, which shows the inefficiency of the management.
  • The company's debt has been a major concern as they are not even able to generate profit to pay off their interest cost, which is visible by a negative interest coverage ratio for FY21.

Arch Pharmalabs Opportunities

  • The Indian Government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programs, lifesaving drugs, and preventive vaccines also augurs well for the pharmaceutical companies.
  • Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as cardiovascular, anti-diabetes, anti-depressants, and anti-cancers, which are on the rise, so as the company is in contract manufacturing and CRAMS they can focus on the respective segment to increase their source of revenue.

Arch Pharmalabs Threats

  • Active Pharmaceutical Ingredients (APIs), or bulk drugs, are raw materials used in the manufacture of medicines or formulations. China was one of the leading countries to produce and sell APIs to the rest of the world until recently. However, with the outbreak of COVID-19 and its origin traced to China, the production of APIs took a hit. This may affect the price and sale of medicines in countries to which Beijing exports the important ingredients.
  • Moreover, the impact is set to be grave, as most of those materials are largely manufactured in the Hubei province. Its capital, Wuhan has been reported as the initial epicenter of the COVID-19 outbreak, and neighboring areas of Zhejiang and Jiangsu are the other two major Chinese centers of medicinal raw material production.
  • Threats include several factors, such as new generic products that arrive in the market, new regulations, new trade barriers, changes to health insurance regulations, and even the lack of availability of qualified staff.
Arch Pharmalabs Rating

  • RECOMMENDATION

    Strong Sell

  • Arch Pharmalabs Detail Info

Industry Statistics

PRIVATE LIMITED

Registered In

India

last Updated

24/08/2022

Registered Date

27/08/1992

Planify Ticker

APLABS

Reg Office: 3rd Floor, Titanic Building, Chandivali Farm Road, Nr. HDFC Bank, Andheri (East) Mumbai - 400072

Visit Website

Frequently Ask Questions

Please find below the procedure for buying stock_name_auto Unlisted Shares at Planify.
• 1. You confirm booking of stock_name_auto Unlisted Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling stock_name_auto Unlisted Shares is 6 months after listing. Hence you can’t sell stock_name_auto Unlisted Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.

Please find below the procedure for selling stock_name_auto Unlisted Shares at Planify.
• 1. We will confirm our buying price of stock_name_auto Unlisted Shares.
• 2. We will give you our client master report and you will transfer the stock_name_auto Unlisted Shares to our demat account.
• 3. We will ask for bank details of yours once the stock_name_auto Unlisted Shares are received in our demat account..
• 4. We will transfer the funds in your bank account within 24 hrs of receiving the stock_name_auto Unlisted Shares.
• 5. Payment will be made in RTGS / NEFT / CHEQUE TRANSFER/IMPS. No CASH DEPOSIT.
• 6. Payment will be given in the same account which is linked to demat account or you need to provide the cancelled cheque shows your name to verify. As per SEBI regulations, the transfer of funds in the third party account is not legal and our policy refrain us from doing so.
Note: The price at which we are buying the share is fixed for 3 days. If you cant sell your stock within 3 days, then the price of that day will be applicable when we receive shares in our demat.

Lock-in period of stock_name_auto Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of stock_name_auto Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of stock_name_auto Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

DIS - Delivery Instruction Slip is the way through which an investor can sell or transfer the stock_name_auto Unlisted Shares from his/her demat account to any other demat account. There are two Types of DIS Slip.
1. Offline-DIS - This is an offline mode of transfer of shares wherein the investors needs to fill DIS form and give it to their broker for transferring the shares. Following are the fields which are required to be filled.
• a. ISIN number of stock_name_auto Unlisted Shares.
• b. Name of stock_name_auto Unlisted Shares
• c. Quantity of stock_name_auto Unlisted Shares
• d. Cosideration Amount
• e. Target DP ID and Client ID
• f. Annexure
2. Online DIS - Some of the broker these days gives facility of transferring the stock_name_auto Unlisted Shares via online DIS. So, please check with your broker whether such facility is available or not. For example: Angel Broking proivdes the facility of Online-DIS from its platform. As an investor he/she simply needs to add a beneficiary into it and send the stock_name_auto Unlisted Shares by filling the details similar to Ofline-DIS.

In the last 4-5 years, the unlisted share market has become quite big and as a result of that, the ticket size has reduced from usual 5-10 Lac to 35-50k in today's scenario. Generally via our Planify platform, if somebody wants to buy Unlisted Shares then minimum investment would be 35-50k.To know about the minimum lot size of stock_name_auto, kindly click on this hyperlink - stock_name_auto.

Yes, buying and selling of unlisted shares in India is 100% legal.

If you sell your shares within 2 years, then you will have to pay Short-term Capital gain on unlisted shares. Short-Term Capital Gain is added in your Income. So, as per individual tax slab you need to pay capital gain tax.

If you sell your shares after 2 years, then you will have to pay Long-term Capital gain on unlisted shares LTCG is 20% with indexation benefits.

Taxes will remain the same irrespective of listing of shares, if bought in unlisted market. Actually, to be eligible for taxes as per listed market, one has to pay STT on buying and selling of shares. But, if you buy in unlisted and sell in listed market, one pay STT only on selling so, taxes of listed market will not be applicable.

If you buy stock_name_auto Unlisted Shares from Planify then these shares can checked in two ways. However, before we tell you the process of checking of shares, it is intimated that as per SEBI regulations, the shares can be transferred in demat account only.
Check credit of stock_name_auto Unlisted Shares Instantly?
• 1.You can download the NSDL or CDSL application from google play-store and check. If you want to check whether your stock broker is registered with NSDL or CDSL then check the following procedure.
• By carefully examining the number format of Demat Account we can easily identify whether the stock broker is registered with CDSL or NSDL.
• Demat Account = DP ID + Client ID. (16 Characters )
• "DP ID is the unique identification of the Broker. Every broker gets a unique number from CDSL or NSDL.By carefully examining the number format of Demat Account we can easily identify whether the stock broker is registered with CDSL or NSDL.
• Client ID is the unique identification of the Client. Every client gets this unique number which represents his/her portfolio.
• In CDSL, all these characters are numbers (1234567891234567) first 8 digits are DP ID and next 8 digits are Client Id whereas in NSDL the first two characters are letters which are in accordance with the country that you are from (IN12345678912345), then 6 unique digits for Broker and next 8 digits are client ID.
• Example:
• CDSL = 12345678(DP ID) and 91234567(Client ID).
• NSDL = IN123456 (DP ID) and 78912345(Client ID).
• Check in brokers application?
• Credit of stock_name_auto Unlisted Shares can be checked in brokers application as well but it takes T+2 days to show the shares.

The stock_name_auto Unlisted Shares are credited in demat account same day of transferring funds in our company's bank account.

The price of stock_name_auto Unlisted Shares can be checked in two ways. First, you can join our telegram channel where on daily basis we share the latest prices of all the unlisted shares in the morning and secondly, you can register on Planify.live platform to see the historical graphs and prices of all the shares at one place.

If you see the thesis of investment in the unlisted shares then it is being done mainly to take the advantage of IPO market. And, if the IPO plans of company get delayed due to market conditions or any other reason then demand suddenly drops in the market. The unlisted market works mainly on demand and supply and if there is no IPO news then getting exit would be difficult.

"Planify is India's fastest and leading marketplace to buy and sell unlisted shares. In the last 3 years, we have already served more than 1 million users on the platform. The total transactions value done from the platform is already more than 100 Crores. The name of our Co-founders Mr. Umesh Paliwal and Dinesh Gupta publish regularly in leading newspapers like MoneyControl, Business-Standard, ET etc for their views on IPO and Unlisted market. In the last 3 years, Planify has made a good name for itself in the industry and gained a trust of their users. So, the new investors should not be worried about any kind of fraud that is mostly happens with unkown brokers in the market while doing investment with Planify."

We at Planify do the valuation based on 2 methods.
• 1. We check the last funding that is being done in the stock_name_auto Unlisted Shares to ascertain the benchmark valuation.
• 2. If there is no funding happened in the company, then we try to find a business similar to stock_name_auto Unlisted Shares in the listed space and do comparison method to ascertain the valuation.
As an investor in the unlisted space, we would always recommend that you must check all the risk parameter carefully before investing in the unlisted space.

We source shares either from the employees or initial investors looking to liquidate their stock_name_auto Unlisted Shares.

Pre-IPO shares means which are planning for an IPO in near future. So, all the shares which are traded on the platform are not Pre-IPO Shares. However, if the company's business is going good and then demand will always be there in the unlisted space, so even if the IPO does not come, the investors can easily liquidate their stock_name_auto Unlisted Shares in the unlisted market itself.

Rules and regulations of SEBI are applicable in the Unlisted space like lock-in period of 6 months, paying of Stamp Duty, and DP Charges for every transaction etc. However, to become an unlisted broker there is no such regulation by SEBI as of yet.

For tracking news and other information about stock_name_auto Unlisted Shares, one can visit our website wherein we post news and other information on daily basis and one can also join our telegram channel.

Fundamental & Comparative valuation models and the forces of demand and supply in the market for unlisted shares dictate the price. These prices are based on our estimates and transaction history of stock_name_auto Ltd unlisted share.

We can generally arrange lot sizes starting with an investment of INR 20,000. To confirm the lot sizes of stock_name_auto Ltd unlisted shares with us.

The financials of stock_name_auto Ltd which includes the P/L of stock_name_auto Ltd and the Balance Sheet of stock_name_auto Ltd is in the financials section.

The annual report of stock_name_auto Ltd is available in the annual report section.